The Promise And Future Of Psychedelics Research The Pulse podcast

Artwork

Contenuto fornito da NPR. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da NPR o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

The Pulse « »
The Promise and Future of Psychedelics Research

2M ago 49:06

Condividi

MP3•Pagina principale dell'episodio

Contenuto fornito da NPR. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da NPR o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Interest in using psychedelics for mental health treatments has taken off in recent years — but the field was just dealt a major blow on August 9, when the Food and Drug Administration rejected a bid by Lykos Therapeutics to approve the first-ever MDMA treatment for PTSD. The agency said it needed more research to show that the drug was safe and effective. The decision means that an active research community that has formed over the last few decades will likely continue as it started — more underground than above ground.
On this episode, we look at the latest on psychedelics and mental health, along with the challenges to moving the research forward. We hear stories about the battle over MDMA, new questions about whether ketamine can actually help treat depression, and a group that says it's found the solution to cluster headaches in psilocybin.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy

… continue reading

601 episodi

Artwork

The Promise and Future of Psychedelics Research

425 subscribers

published 2M ago

Condividi

MP3•Pagina principale dell'episodio

Contenuto fornito da NPR. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da NPR o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Interest in using psychedelics for mental health treatments has taken off in recent years — but the field was just dealt a major blow on August 9, when the Food and Drug Administration rejected a bid by Lykos Therapeutics to approve the first-ever MDMA treatment for PTSD. The agency said it needed more research to show that the drug was safe and effective. The decision means that an active research community that has formed over the last few decades will likely continue as it started — more underground than above ground.
On this episode, we look at the latest on psychedelics and mental health, along with the challenges to moving the research forward. We hear stories about the battle over MDMA, new questions about whether ketamine can actually help treat depression, and a group that says it's found the solution to cluster headaches in psilocybin.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy

… continue reading

601 episodi

Tutti gli episodi

×

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

Ascolta più di 500 argomenti